PBYI News and Press, Puma Biotechnology Inc From 12/10/20

Puma Biotechnology (PBYI) jumps 9% after-hours after presenting efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the Phase III ExteNET trial at the 2020 Virtual San Antonio Breast Cancer Symposium. The trial included 2,840 patients who received ner...

Results show continued efficacy of neratinib in patients with HER2-positive early stage breast cancer Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that efficacy results of neratinib in HER2-positive early stage breast cancer (eBC) from the ...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented updated results from the ongoing Phase II SUMMIT trial of neratinib at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) that is currently taking place. The presentation entitled, “Latest f...

Puma Biotechnology ([[PBYI]] -5.7%) said the European Board of Appeals has rejected the opposition to EP Patent 1848414 initiated by a Boehringer Ingelheim entity.EP Patent 1848414, originally granted in April 2011 covers the use of irreversible EGFR inhibitors in treating gefitinib and/or er...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib r...

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of 10 abstracts that will be presented at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) from Dec 8-11, 2020. Abstracts are available to the public online on the SABCS website at ...

The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Puma Biotechnology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Puma Biotechnology Inc (NASDAQ: PBYI) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Puma Biotechnology Inc (PBYI) Q3 2020 Earnings Call Transcript

Puma Biotechnology, Inc. (PBY) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Executive Officer, President, and Chairman of the Board Jeff Ludwig – Chief Commer...

Puma Biotechnology (PBYI): Q3 Non-GAAP EPS of -$0.60 misses by $0.46; GAAP EPS of -$0.79 misses by $0.40.Revenue of $50.8M (-9.9% Y/Y) misses by $2.17M.Shares -7.9%.Press Release For further details see: Puma Biotechnology EPS misses by $0.46, misses on revenue